FindTrial
Sign In

Randomized control trial of the conditioning BUCy regimen with fludarabincin instead of cyclophosphomide in allogeneic hematopoietic stem cell transplantation from identical siblings

Randomized control trial of the conditioning BUCy regimen with fludarabincin instead of cyclophosphomide in allogeneic hematopoietic stem cell transplantation from identical siblings

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-09000470
Enrollment
Unknown
Registered
2009-07-15
Start date
2009-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancies

Interventions

Group B:cyclophosphomide, 1.8g/m2/d*2d, intravenouly
Group A:fludarubincin, 30mg/m2/dx3d, intravenously

Sponsors

People's hospital of Peking University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Male and female aged 18 to 55 years old; 2. Hematological malignancies indicating for allogeneic transplantation, with identical sibling as donor, with indication for the previous modified BUCY conditioning; 3. Signed informed consent.

Exclusion criteria

Exclusion criteria: Patients whose organ function can not tolerate the myeloablative transplantation.

Design outcomes

Primary

MeasureTime frame
Transplantation related mortality;Rate of survival and relaps;—

Secondary

MeasureTime frame
Incidence of engraftment, opportunistic infection,;—

Countries

China

Contacts

Public ContactXiaojun Huang
xjhrm@medmail.com.cn+86 010 88326006

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 22, 2026